BPC-157 + TB-500 Blend — Research, Dosing & Price Guide

The BPC-157 + TB-500 blend, commonly known as the 'Wolverine Stack,' combines the two most potent healing peptides available into a single vial for convenience and synergistic effect. BPC-157 drives angiogenesis, growth factor upregulation, and NO system stabilization while TB-500 (Thymosin Beta-4) promotes cell migration through actin regulation and provides potent systemic anti-inflammatory effects. Together they address the structural, vascular, inflammatory, and cellular components of tissue injury — making this the gold standard healing protocol in the peptide community.

This blend leverages two complementary and synergistic healing mechanisms that together cover virtually every aspect of tissue repair: **BPC-157's contribution:** Upregulation of VEGF, FGF-2, and growth hormone receptors drives new blood vessel formation (angiogenesis) at injury sites. Activation of the FAK-paxillin pathway promotes fibroblast and endothelial cell migration for wound closure. NO system stabilization maintains vascular tone and blood flow. Growth factor receptor amplification enhances the body's responsiveness to endogenous repair signals. **TB-500's contribution:** Thymosin Beta-4 sequesters G-actin monomers and promotes their polymerization into F-actin filaments, which is essential for cell migration, the fundamental process by which repair cells reach injury sites. It potently downregulates NF-κB, the master inflammatory transcription factor, reducing TNF-α, IL-1β, and IL-6 production. TB-500 also promotes hair follicle stem cell migration and has unique cardiac repair properties. **Synergistic interactions:** The combination creates an environment where: (1) BPC-157 builds new blood vessels to supply the injury site while TB-500 enables repair cells to migrate there; (2) TB-500 controls inflammation while BPC-157 drives reconstruction; (3) BPC-157 provides local healing signals while TB-500 provides systemic anti-inflammatory coverage. The result is consistently faster and more complete healing than either peptide alone.

• Both peptides have independent and extensive bodies of preclinical evidence — BPC-157 with 100+ studies and TB-500/Thymosin Beta-4 with decades of research including cardiac repair, wound healing, and neuroprotection.
• BPC-157 and TB-500 target fundamentally different but complementary pathways: BPC-157 drives angiogenesis and growth factor signaling while TB-500 enables cell migration through actin dynamics and suppresses inflammation through NF-κB. There is virtually no mechanistic overlap, maximizing synergy.
• TB-500 (Thymosin Beta-4) demonstrated cardiac repair in a Phase I/II clinical trial — improving cardiac function in acute myocardial infarction patients, complementing BPC-157's vascular protective effects.
• Anecdotal and clinical community reports consistently indicate faster and more complete healing outcomes with the BPC-157/TB-500 combination compared to either peptide used individually.
• The combination addresses all four phases of wound healing: hemostasis (vascular protection), inflammation (NF-κB suppression), proliferation (angiogenesis + cell migration), and remodeling (growth factor-driven tissue maturation).

• Standard blend vial: 5 mg BPC-157 / 5 mg TB-500 per vial (10 mg total). Reconstitute with 2 mL bacteriostatic water for 2.5 mg/mL of each peptide.
• Standard healing dose: 0.1–0.2 mL daily (250–500 mcg of each peptide), injected subcutaneously near the injury site. This is the most common protocol for musculoskeletal injuries.
• Loading phase (acute injuries): 500 mcg of each peptide daily for the first 2–4 weeks, then reduce to 250 mcg of each daily for maintenance.
• Systemic protocol (gut healing, general recovery): Inject into abdominal subcutaneous fat, 250–500 mcg of each daily.
• TB-500 front-loading variation: Some protocols use the blend daily for the first 2 weeks, then switch to every-other-day dosing, reflecting TB-500's longer biological activity.
• Typical cycle: 6–12 weeks for injury healing, depending on severity. Minor injuries (grade 1 sprains, mild tendinitis) may resolve in 4–6 weeks. Major injuries (partial tears, post-surgical) may require 8–12 weeks.
• Also available in 10 mg/10 mg vials for extended protocols or higher-dose needs.

Known Side Effects

• Injection site reactions — redness, mild swelling, or irritation, particularly during the first few days. More common with the blend due to higher total peptide concentration per injection.
• Mild headache — reported occasionally, usually during the first week of use.
• Temporary fatigue — some users report mild tiredness during the initial loading phase as the body diverts resources toward healing.
• Mild nausea — infrequent, typically associated with higher doses.
• Water retention — TB-500 can cause mild temporary water retention in some users. Usually resolves within the first 1–2 weeks.
• Theoretical VEGF/angiogenesis concern for those with active malignancies — same precaution as standalone BPC-157.

Safety Profile

The BPC-157/TB-500 blend inherits the safety profiles of both individual components, which are among the safest peptides in research use. BPC-157 has no established lethal dose in animal studies, and Thymosin Beta-4 has been through human clinical trials (for cardiac repair and wound healing) with excellent tolerability. No serious adverse events are attributed to either compound in published literature. Contraindications are the same as for individual components: active malignancy (precaution due to angiogenic potential), pregnancy/breastfeeding, and known hypersensitivity. The blend does not suppress endogenous hormone production and requires no PCT. Individuals on anticoagulants should be aware that TB-500 may have mild effects on platelet function, though clinically significant interactions have not been reported. The combination can be used alongside most medications without concern for CYP450 interactions.

Days 1–3: Anti-inflammatory effects begin. Pain and swelling at the injury site may noticeably decrease. The combination often produces faster symptom relief than either peptide alone. Week 1: Healing acceleration is apparent. Range of motion improves, pain decreases significantly. New blood vessel formation and cell migration are actively occurring at the tissue level. Weeks 2–4: This is the peak healing period. Users with acute injuries (sprains, strains, minor tears) often report 50–70% improvement. Chronic injuries that had plateaued begin progressing. Surgical recovery patients report faster-than-expected healing. Weeks 5–8: Tissue remodeling and maturation. The healed tissue gains strength and organization. Many acute injuries are fully resolved. Chronic tendinopathies show continued improvement. Weeks 9–12: Final remodeling phase. Tissue quality continues to improve. Most users taper dosing or discontinue as healing goals are met.

Prices sourced from peptides.gg marketplace. Prices may vary.